Global Blood Therapeutics’ candidate (Voxelotor) has a lot of potential for SCD.
There are a lot of articles on Sickle Cell Disease (SCD) which I strongly invite you to read.
From a Technical Analysis point of view, I like what I see in GBT's chart.
For me, the stock ended an a-b-c correction and is now preparing to move forward.
Confirmation is needed but overall the chart looks robust.
There are a lot of articles on Sickle Cell Disease (SCD) which I strongly invite you to read.
From a Technical Analysis point of view, I like what I see in GBT's chart.
For me, the stock ended an a-b-c correction and is now preparing to move forward.
Confirmation is needed but overall the chart looks robust.